Literature DB >> 8863139

High yield incorporation of plasmid DNA within liposomes: effect on DNA integrity and transfection efficiency.

G Gregoriadis1, R Saffie, S L Hart.   

Abstract

Effective use of liposomes in gene therapy requires high yield incorporation of nucleic acids within vesicles which protect their content from nuclease attack and facilitate transfection: To that end, pGL2 plasmid DNA (3.99 x 10(6) Daltons) expressing the luciferase reporter gene was incorporated quantitatively (40-92% of the DNA used) by a mild procedure into neutral and negatively or positively charged multilamellar liposomes which offered considerable protection from deoxyribonuclease attack. Smaller vesicles (210-383 nm diameter) produced from such liposomes, retained much of the original content of DNA which was still significantly inaccessible to the enzyme. Liposomal plasmid DNA was found to retain its structural integrity and to transfect cells in vitro in relation to the size and surface charge of the vesicles. Such DNA-incorporating liposome constructs could prove effective for plasmid DNA expression in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8863139     DOI: 10.3109/10611869609015966

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  9 in total

1.  Unraveling electronic energy transfer in single conjugated polyelectrolytes encapsulated in lipid vesicles.

Authors:  Pierre Karam; An Thien Ngo; Isabelle Rouiller; Gonzalo Cosa
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

Review 2.  Genetic vaccines: strategies for optimization.

Authors:  G Gregoriadis
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

3.  Protective effect of DNA-mediated immunization with liposome-encapsulated GRA4 against infection of Toxoplasma gondii.

Authors:  Rui Chen; Shao-Hong Lu; Qun-Bo Tong; Di Lou; Dong-Yan Shi; Bing-Bing Jia; Guo-Ping Huang; Jin-Fu Wang
Journal:  J Zhejiang Univ Sci B       Date:  2009-07       Impact factor: 3.066

4.  Characterization of zwitterionic phosphatidylcholine-based bilayer vesicles as efficient self-assembled virus-like gene carriers.

Authors:  Reihaneh Ramezani; Majid Sadeghizadeh; Mehrdad Behmanesh; Saman Hosseinkhani
Journal:  Mol Biotechnol       Date:  2013-10       Impact factor: 2.695

5.  Characterization of DNA/lipid complexes by fluorescence resonance energy transfer.

Authors:  Catarina Madeira; Luís M S Loura; M Raquel Aires-Barros; Aleksander Fedorov; Manuel Prieto
Journal:  Biophys J       Date:  2003-11       Impact factor: 4.033

6.  Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice.

Authors:  Jae Won Rhee; Dongbum Kim; Byung Kwon Park; Sanghoon Kwon; Sunhee Cho; Ilseob Lee; Man-Seong Park; Jae-Nam Seo; Yong-Sun Kim; Hong Seok Choi; Younghee Lee; Hyung-Joo Kwon
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

7.  Production of antibodies with peptide-CpG-DNA-liposome complex without carriers.

Authors:  Dongbum Kim; Sanghoon Kwon; Jae Won Rhee; Kwang Dong Kim; Young-Eun Kim; Cheung-Seog Park; Myeong Jun Choi; Jun-Gyo Suh; Doo-Sik Kim; Younghee Lee; Hyung-Joo Kwon
Journal:  BMC Immunol       Date:  2011-05-18       Impact factor: 3.615

8.  Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers.

Authors:  Sanghoon Kwon; Dongbum Kim; Byoung Kwon Park; Sunhee Cho; Kwang Dong Kim; Young-Eun Kim; Cheung-Seog Park; Hyun-Jong Ahn; Jae-Nam Seo; Kyung-Chan Choi; Doo-Sik Kim; Younghee Lee; Hyung-Joo Kwon
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

9.  Priming with a DNA vaccine and boosting with an inactivated vaccine enhance the immune response against infectious bronchitis virus.

Authors:  Zicheng Guo; Hongning Wang; Tai Yang; Xue Wang; Dan Lu; Yulin Li; Yi Zhang
Journal:  J Virol Methods       Date:  2010-03-20       Impact factor: 2.014

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.